Clinical Trials
6 trialsNCT05483933 2025-12-23
Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers
Shattuck Labs, Inc.
Phase 1 Completed
NCT01314105 2025-02-13
BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Advanced Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Cancer
Boehringer Ingelheim
Phase 1 Completed
NCT05261490 2024-11-19
Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer
Pfizer
Phase 1/2 Terminated
NCT02580058 2023-07-10
JAVELIN Ovarian 200
Pfizer
Phase 3 Completed
NCT02431559 2022-10-10
Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer
Ludwig Institute for Cancer Research
Phase 1/2 Completed
NCT01329549 2014-11-27
Dose Escalation Study of BIBF 1120 in Combination With Carboplatin and PLD in Relapsed Ovarian Cancer (OC)
Boehringer Ingelheim
Phase 1 Terminated